How many insider disclosures are linked to BridgeBio Oncology Therapeutics, Inc.?

Available records link 16 public disclosures to BridgeBio Oncology Therapeutics, Inc., sourced from SEC (Form 4).

Who is the top reporting insider at BridgeBio Oncology Therapeutics, Inc.?

The top reporting insider at BridgeBio Oncology Therapeutics, Inc. is Chen Bihua, based on the count of public filings.

What declared insider buy and sell totals are available for BridgeBio Oncology Therapeutics, Inc.?

Across the available history, declared buys total 0 and disposals 0.

InsiderTradesSIGMA

InsidersTradesSigma

← Companies ★ Sign in to follow

BridgeBio Oncology Therapeutics, Inc. Stock: price and insider trades · United States · SEC (Form 4)

Source idSEC:bridgebio-oncology-therapeutics-inc-00bb9f·SEC (Form 4)Mcap US$736M

SEC (Form 4)

Track the BridgeBio Oncology Therapeutics, Inc. share price and the full directors' dealings record of the company, a listed issuer based in United States. Shares trade on the US market, under the supervision of SEC (Form 4). Market capitalisation: €736m. The latest transaction was filed on 6 July 2026 (Retenue fiscale). Among the most active insiders: Chen Bihua. The full history is openly available.

Insider Decl.

n/a

Thresholds

n/a

Buy Volume

n/a

Sell Volume

Analyst consensus: bullish or bearish?

Analysts rate BridgeBio Oncology Therapeutics, Inc. Strong Buy (bullish), based on 10 analysts. Average price target: US$24.90.

30Σ signal

This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.